Selected article for: "activity mechanism and adaptive immunity"

Author: Frebel, Helge; Oxenius, Annette
Title: The risks of targeting co-inhibitory pathways to modulate pathogen-directed T cell responses
  • Cord-id: 3f0oh9xs
  • Document date: 2013_1_16
  • ID: 3f0oh9xs
    Snippet: The identification of T cell co-inhibition as a central mechanism in the regulation of adaptive immunity during infectious diseases provides new opportunities for immunotherapeutic interventions. However, the fact that T cell activity is frequently downregulated during pathogen-directed responses suggests a pivotal physiological role of co-inhibitory pathways during infectious disease. Reports of exacerbated immunopathology in conditions of impaired co-inhibition foster the view that downregulat
    Document: The identification of T cell co-inhibition as a central mechanism in the regulation of adaptive immunity during infectious diseases provides new opportunities for immunotherapeutic interventions. However, the fact that T cell activity is frequently downregulated during pathogen-directed responses suggests a pivotal physiological role of co-inhibitory pathways during infectious disease. Reports of exacerbated immunopathology in conditions of impaired co-inhibition foster the view that downregulation of T cell activity is an essential negative feedback mechanism that protects from excessive pathogen-directed immunity. Thus, targeting co-inhibitory pathways can bear detrimental potential through the deregulation of physiological processes. Here, we summarize recent preclinical and clinical interventions that report immune-related adverse events after targeting co-inhibitory pathways.

    Search related documents:
    Co phrase search for related documents
    • activity safety and adaptive immune response: 1
    • activity safety and adenovirus infection: 1
    • acute infection and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute infection and adaptive immunity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute infection and adaptive immunity regulation: 1, 2, 3, 4
    • acute infection and additional risk: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • acute infection and adenovirus infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute infection and liver pathology: 1, 2, 3, 4, 5, 6, 7
    • acute infection and local infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute viral infection and adaptive immune response: 1, 2, 3, 4
    • acute viral infection and adaptive immunity: 1, 2
    • acute viral infection and adenovirus infection: 1, 2, 3
    • acute viral infection and local infection: 1
    • adaptive immune response and adenovirus infection: 1
    • adaptive immune response and liver pathology: 1
    • adaptive immune response and local infection: 1, 2
    • adaptive immunity and additional risk: 1, 2, 3
    • adaptive immunity and liver pathology: 1
    • adaptive immunity and local infection: 1, 2